{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:29:19Z","timestamp":1790386159558,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,12,22]]},"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Only few studies have systematically investigated neuropsychiatric aspects in patients with Cushing's disease (CD). Pain syndromes have been described in patients with pituitary adenomas, but so far no systematical investigation has been conducted in patients with CD. Additionally, CD has an association with cardiometabolic comorbidities which ultimately leads to increased morbidity and mortality. Long-term treatment of the hypercortisolic state cannot prevent the persistence of an unfavourable cardiometabolic risk profile. Finally, chronic hypercortisolism is known to impact the health-related quality of life (HRQoL). We aim to systematically investigate the neuropsychiatric and cardiometabolic comorbidities, as well as assess the HRQoL, in patients with previously diagnosed CD in a longitudinal fashion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this longitudinal study, we will assess 20 patients with CD displaying biochemical control 24\u2005months after recruitment in the initial cross-sectional study (n=80). This will be a mixed cohort including patients after surgical, after radiation therapy and\/or under current medical treatment for CD. Primary outcomes include changes in mean urinary free cortisol and changes in specific pain patterns. Secondary\/exploratory neuropsychiatric domains include depression, anxiety, personality, sleep, body image and quality of life. Secondary\/exploratory cardiometabolic domains include anthropometric parameters, cardiometabolic risk biomarkers and insulin resistance. Additional domains will be investigated if warranted by clinical indication. Safety assessment under medical therapy will include liver enzymes, ECG abnormalities and hyperglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Risk of damage from study-conditioned measures is very small and considered ethically justified. Dual-energy X-ray absorptiometry may call for detailed fracture risk assessment. However, the radiation dose is very small and only administered on clinical indication; therefore, it is considered ethically justified. This protocol has been approved by the local medical ethics committee.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-006134","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T00:44:33Z","timestamp":1427589873000},"page":"e006134","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Neuropsychiatric and cardiometabolic comorbidities in patients with previously diagnosed Cushing's disease: a longitudinal observational study"],"prefix":"10.1136","volume":"5","author":[{"given":"C","family":"Dimopoulou","sequence":"first","affiliation":[{"name":"Department of Neuroendocrinology, Max Planck Institute of Psychiatry (MPIP), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Geraedts","sequence":"additional","affiliation":[{"name":"Department of Neuroendocrinology, Max Planck Institute of Psychiatry (MPIP), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G K","family":"Stalla","sequence":"additional","affiliation":[{"name":"Department of Neuroendocrinology, Max Planck Institute of Psychiatry (MPIP), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sievers","sequence":"additional","affiliation":[{"name":"Department of Neuroendocrinology, Max Planck Institute of Psychiatry (MPIP), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2025121409482588000_5.3.e006134.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04172-6"},{"key":"2025121409482588000_5.3.e006134.2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.3.912"},{"key":"2025121409482588000_5.3.e006134.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(01)00059-2"},{"key":"2025121409482588000_5.3.e006134.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.5.1949"},{"key":"2025121409482588000_5.3.e006134.5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1375"},{"key":"2025121409482588000_5.3.e006134.6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0762"},{"key":"2025121409482588000_5.3.e006134.7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh525"},{"key":"2025121409482588000_5.3.e006134.8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/cen.12564","article-title":"Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome","volume":"81","author":"Crespo","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025121409482588000_5.3.e006134.9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/cen.12224","article-title":"Hippocampal dysfunction in cured Cushing's syndrome patients, detected by (1) H-MR-spectroscopy","volume":"79","author":"Resmini","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025121409482588000_5.3.e006134.10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.8.3662"},{"key":"2025121409482588000_5.3.e006134.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02168.x"},{"key":"2025121409482588000_5.3.e006134.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2005.01.010"},{"key":"2025121409482588000_5.3.e006134.13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0766"},{"key":"2025121409482588000_5.3.e006134.14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000355622","article-title":"Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing's disease patients in the course of the disease","volume":"98","author":"Milian","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2025121409482588000_5.3.e006134.15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40271-013-0012-5","article-title":"Psychometric evaluation of the Cushing's Quality-of-Life questionnaire","volume":"6","author":"Nelson","year":"2013","journal-title":"Patient"},{"key":"2025121409482588000_5.3.e006134.16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0308"},{"key":"2025121409482588000_5.3.e006134.17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-014-0126-1","article-title":"Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX(\u00ae) algorithm useful?","volume":"37","author":"Trementino","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"2025121409482588000_5.3.e006134.18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","article-title":"Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?","volume":"25","author":"Scillitani","year":"2014","journal-title":"Osteoporos Int"},{"key":"2025121409482588000_5.3.e006134.19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF03345431","article-title":"Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications","volume":"35","author":"Arnaldi","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"2025121409482588000_5.3.e006134.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12189","article-title":"Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome","volume":"79","author":"T\u00f3th","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025121409482588000_5.3.e006134.21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0375"},{"key":"2025121409482588000_5.3.e006134.22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000338408","article-title":"Increased prevalence of anxiety-associated personality traits in patients with Cushing's disease: a cross-sectional study","volume":"97","author":"Dimopoulou","year":"2013","journal-title":"Neuroendocrinology"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-006134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:48:36Z","timestamp":1765734516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-006134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,27]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1136\/bmjopen-2014-006134"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-006134","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}